Your browser doesn't support javascript.
loading
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.
Reutter, Theresa; Fassunke, Jana; Püsken, Michael; Weber, Jan-Phillip; Binot, Elke; Eisert, Anna; Fischer, Rieke; Nogova, Lucia; Riedel, Richard; Schaufler, Diana; Scharpenseel, Heather; Scheffler, Matthias; Schulz, Holger; Waldschmidt, Dirk-Thomas; Zander, Thomas; Merkelbach-Bruse, Sabine; Schirmacher, Peter; Büttner, Reinhard; Wolf, Jürgen; Michels, Sebastian.
Afiliação
  • Reutter T; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Fassunke J; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Püsken M; Faculty of Medicine and University Hospital Cologne, Institute for Diagnostic and Interventional Radiology, University of Cologne, Cologne, Germany.
  • Weber JP; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Binot E; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Eisert A; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Fischer R; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Nogova L; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Riedel R; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Schaufler D; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Scharpenseel H; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Scheffler M; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Schulz H; Practice for Clinical Hematology and Oncology, Frechen, Germany.
  • Waldschmidt DT; Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Zander T; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Merkelbach-Bruse S; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Schirmacher P; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Büttner R; Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Wolf J; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
  • Michels S; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany.
JCO Precis Oncol ; 7: e2200467, 2023 04.
Article em En | MEDLINE | ID: mdl-37079858
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: JCO Precis Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: JCO Precis Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha